TW492876B - New dosage forms of cyclosporine for oral application with single composition and high bioavailability and usual procedure of their manufacture - Google Patents
New dosage forms of cyclosporine for oral application with single composition and high bioavailability and usual procedure of their manufacture Download PDFInfo
- Publication number
- TW492876B TW492876B TW084108225A TW84108225A TW492876B TW 492876 B TW492876 B TW 492876B TW 084108225 A TW084108225 A TW 084108225A TW 84108225 A TW84108225 A TW 84108225A TW 492876 B TW492876 B TW 492876B
- Authority
- TW
- Taiwan
- Prior art keywords
- cyclosporine
- pharmaceutical composition
- item
- weight
- patent scope
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Description
492876 A7 _B7 _ 五、發明說明(/ ) / …一 本發阴係關於環孢靈,特別是環孢靈A ,對於口服施 周所包含的液體配方。 環孢靈是由徵生耢所產生之天然的環狀胜M e 環®靈 中最重要的代表是環孢靈A ,它被用在擷制器官排斥的移 植治療和骨髓移植上。環孢靈A的徵生®產物及分離和純 化至非结晶無色粉末,其本質上已在德國專利案24 5 Γ— Ο Γ-* ΓΛ r+t +FT .
ο ο o ^ m m :J 環抱靈A 越來越多被周在自體免疫疾病的處理上 5 例牛皮癖(P s 〇 r i a s i s), 葡萄膜炎(u n e i t i s ), 賢病變症 候群(nephrotic syndronOM 及其飽 0 環孢靈的抗發炎及抗寄生蟲的特性也被描逑。 因為環孢靈疏水性的特性,要產生造戚此活性成份高 度生物可利周性的製藥組成是很困難的。實際上,已知的 _量型式顯示S在藥理動力學變數上招當廣的儒體肉和假 體間變異t生·。在招同的謂量時,Μ疲内環31靈的量在不同 病入閭的變異可達到5 0 %。即使在一儷相同的病人内其 吸牧量的變異&很大c但是,免疫抑制的治療依賴在爾量 依賴副作周和移植器官排斥之間相當窄的治療窗中。 不好的生物利羯搜乃特別歸因於環孢靈在包含水的颚 量形式混合物中的低溶解度。 有很多入企圖去解決這些製藥上的問題。 已知且商業上可提供的謂量形式為親脂性和親水性溶 麵的複雜条統和可溶的清潔劑,並帶有溶解環孢靈和保持 本纸張尺度適周中國國家標準(CNS)A4規格(210 X 297公釐〉 (請先閱讀背面之注意事項再填寫本頁)
492876 A7 B7 五、發明說明( V)
它們在 />α «-Ρ· ΛΛτ* m m w i工片ii ^ 丢 m 33 I h rr: uj 4j ,ΨΛττ .^ i± W M '^u t. i XL m icK bL ^ ...哗 迫 v ~m 其 m 旦 rf-l· i±± J^L itu pq α τ ±n ±± tJl ΕΕί -4-ft-i CD -£?p iJll用安S iB 式包含 A VT 3* O Si表面 mae ^i_ 4-ί<κ·. m jb m rriiri· & φ^4- 昭 J>C ί工 ίϊ*τ ί志 ·、.+ W f4C; i±. m m 3 8 8 3 ό 0 7顯不]史周油以反酒1¾ 媒介物。棍據lit專利寨,商業上可提 溶疲包含徹欖油,酒精和當作表面活 f i 1®。但是&配方會留下問題。 審通常有一令入不悅的氣祿和/或祿 不飽和脂詰酸的油容易腐敗c 的配方中須要相對之高含量的酒精。 對小孩施用此產品上會造成®難,並 這個目的而使用瑱充膠囊時,必須増 完成的精心工作。 案2 ,222 ,770的新頴劑量形 產品至溶液狀的途徑。這些系統包括 一有活性組成物,親脂性,親水性層 雜条統ϋ ifc形態的系統會造成交互反 所使羯的其中一種物質對病入衙言非 水溶液系統内的溶液中的目的。它們至少包含四個 ,名稱為活注組成物,植物油,酒精和一種表®活 國專利案4, -W- KA?衣占丨 /r*^* AtJ~r 六檢_连::¾ d li 飲羯的環孢靈 X 1 D ii L a d r a 表面活搜媒介 it之外,含有 -V, -T^ £rr Ziv 久,tt包3個 高酒精含量在 -fcr AAt RR 3¾ · 龅仔P li问邊 ϋ 為了避免蒸發 泡包装法包装 露在G Β專利 由微、?L跋觀&勺 個成份,形成 活性物質的複 的增加,Μ及 的危機之增加。 國專利案39 ,24,207掲露一生產施用靜腿 羯的樣疋水搭液m注射丨谷液之過程,其中 )Μ重量計一份的環孢靈 木紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) -------*--------I 一 492876 A7 B7 五、發明說明(3 b ) K重量計8至1 3份的一或多種單詣飽和羥脂W 酸及聚乙二醇和 羥醇混合 ••it/· -r- tJ_ 1¾ 不叙土 m is ^ 讲乂 m ⑽河 所有 f 工本 r/j V 上小 在一起 產td和 破壞生 商業上 油,小 Μ及一或多種漬 計1至 _ fLL u i± Mi 研究。 鶴可利 -qpr Λθ 5:ιϊ 口」符ΐ·ϋ 麥油, :在7!挪 Ϊ ^Jrs 如C Y - -fr LL^ ϋ 之 ίχ: 士 人 £^¥3 t±^ ϋ: 一漶疋 的釋放特 用超音波 _行是圍 成_量形 tK傲 ;&為 口」 X、)上 2¾ a ) f^)-x rs -Tit? wj m m m b ) A ·/ V ri / A 製藥形 及徵· kxL· , i士 1± u ia 生成無 難的ύ 式是較 本發明 飲用溶 提及的 Μ重量 當作活 Μ重量 式是特 顆粒的 些形式 溶劑正 它同樣 不適合 驁奇的 疲或膠 hr 日 S ~zrf 问起KJ 計〇 * iOJL ί/\ Ί *± )136 m 計6至 3汾的 專利寨 為了周 OH .liL· · nj ι± -的劑量 玉米油 單或聚 a 及特別 別遺當 彤式並 戸 典 士入 w π < 菱形结 ί£顯示 的。 發現具 囊型式 Γ I Λ77 >j\ m m 5至2 1個或多個 和/或聚一 内能葰用來□服的製藥形式: 水稀釋這些配方,環孢靈沈 型式包括油性,親脂的組成 nja 單 …或二 羥醇類 甘油IS ) 0 5 4專利寨运明结晶xKj 是 CY-Α/Χ-ί I I , 的。這些配方說包含環孢靈 且有更好的穩定性或更良好 局部皮膚或局部眼睛使周。 晶形式的方法在企業層次上 無故定形式的環孢靈對於生 簡單組成和高生_可利用S 之□服施用的環孢靈劑量形 法,其包含: ,最好是1份的多個無晶形
5份的IS和的C (請先閱讀背面之注意事項再填寫本頁) 訂---- -線! 衣紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 492876 A7 _B7 —…_ 五、發明說明(屮) ;-、 0至C 2 2 S脂肪駿之一或多種聚乙二醇單i旨;最好是S 0 L U T 0 L © HS 15,g[3 聚乙二醇一660 — 12-(證基)一硬脂酸酷, c ) K重量計 1 至3 ,最好是2份的一或多種單或多 羥醇當作共溶劑,最好是乙醇和丙二醇環孢靈的溶解度相 當地增加,特別是K水稀釋而維持著這些量特定的比例時 0 這遷不能正常迆被假定因為劑量型式使周脂肪酸的聚 乙二醉s§只當作疏水層和親水層間額外的溶解質。 因此所有入對於如tt的一種配方能顯示商業產品的生 物平衡大為驚訝(見上方)。 實際上,它無法預言如此的一個簡單而無親脂成汾的 配方能夠達到茹tt高的生锪可利周性。 更進一*步發現M D服施用力式精羅地使用無晶形的 S靈,盈環孢靈含量大於5 %的配方,可造成相當好的溶 液特性,經水稀釋後仍能讓持為一穩定,清澈的溶液。 因此,本發明係關於口服劑量形式,為可飲用溶疲或 是包裝在膠囊内,均包括K下成份在K下的比例:
a) Μ重量計0 + 5至2 ,最好是1份的一或多個環 孢靈,特別是Μ無晶彩被使用的環孢靈Α或G fa ) Μ重量計6至9 ,最好是7 * 5份的飽和的C 1 0至C 2 2羥脂訪駿之一或多種聚乙二醇單酷;最好是S 0LUT0L® HS 15 衣紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) ^ ·ϋ 1 ·ϋ II 1-1 一 ov a n I n I m Λ/Μβ ϋ I n i r— — — — — — — 492876 A7 _B7 _ —_ 五、發明說明(/ ) C )以重量計1至3 ,最好是2份的一或多種覃或多 羥醇當作共溶劑,最好是乙醇和丙二醇 根:據本發明,在生產的過程中,必須小心量的比例要 讓持,並且環孢靈一開始即要在室溫下持續攪拌使之完全 溶解於酒精内,隨後在仍為室溫攪择下SO入丙二醇和S 〇丨u t ο 1⑬ H S 1 5。過程產生的溶液包含 每毫升1 0 0毫克的活性成份。K可歆周溶疲或膠囊形 式完成是在一已知的影式下進行,例5D在每個膠囊肉包含 100毫克,50毫克或25毫克的活性組成物。 棍據本發明之組成的生產在下面實洌中詳IS說明 : 袖:/£;ϊϊ 1 1 0 0公克非固定形式的環孢靈A在室溫下S浮而溶 於1 27毫升的酒精内。隨後,進一步再於室溫下攪拌, 加入9 6毫升的丙二醇。得到一環孢靈A清激溶液之後, 入7 5 0公克的S o i u t o i ® H S 1 5並進一 步攪拌。可得到一澄漬、黏稠包含每毫升1 00毫克環孢 靈A的溶液。 在實例1中所升成的環孢靈A溶液甩水Ml :40的 比例稀釋。所彤成的溶疲可維持數個月的漬澈和穩定。 衣紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) ▼-------訂-------·!線!
Claims (1)
- 492876 -, A8 ; ' Ί :. B8 :/.、 入C8 、 D8 — —— ~— f ' 七、申請專利範圍 丨乂Γ ^, (請先閲讀背面之注意事項再填寫本頁) 1 * 一種□服環ίΜ靈藥學組成物,其為哥飲用溶液或 ®囊影式,包含: a ) Μ重量計0 + 5至2份的一或多種無晶形環JS靈 當作活性成汾 D ) 从重量 §十 b 主 0 1方 u'j C 1 0 至匕 ε 2 證,§§ 3® 酸 《ί! 一或多種聚乙二醇單iS c) Μ重量計1至3份的一或多種翬或多羥醇當诈共 溶Si。 2 *根據帛請專利範圍第1項的藥擧組成物,使甩非 晶形環孢靈A或環孢靈G當作活性成份。 3 * —種製儀□跟環孢靈藥學組成物的方法,該藥學 組成物為可飲用溶疲或膠囊形式,苜先在室溫下攪拌 a) 每1 00公克無晶形環孢靈,溶於1 27毫升的 酒精内 b) 又當在室溫下攪拌時,加入96毫升的丙二醇, 隱後又於室溫下攪拌, c )加入750公克的聚乙二醇—660— 1 2 —( 羥基)-硬脂酸脂,成為一清澈,黏稠的環孢靈溶液,並 Μ已茹的方式裝Μ成為可飮用的溶液或是包裝成為膠囊。 4 +如串請專利範圍第1項之藥學組成物,其包含Μ 重量計1份之一或多種無晶形環孢靈。 5 ♦如Φ譆專利範圍第1項之藥學組成物,其包含Μ 7 . 5份之飽和C 1 0至C 2 2羥脂訪酸之一或多種聚乙二 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 492876 A8 B8 C8 D8 六、申請專利範圍 醇覃酯。 (請先閲讀背面之注意事項再填寫本頁) 6 ▲ 50串請專利範圍第1項之藥學組成物,其包含Μ 重量計2扮的一或多種單或多證醇。 7 ♦如串請專利範圍第1項之藥學組成物,其中C 1 0至C 2 2羥脂肪酸之一或多種聚乙二醇覃酯為聚乙二 醇一660—12— (羥基)—硬脂酸脂 8 *如Φ請專利範圍第1項之藥學組成物,其中輋或 多羥醇為乙醇及/或两二醇 9 * Φ請專利範圍第3項之的方法 5 其中無晶彩環 孢靈為環孢靈A。 1 〇 +如串請專利範圍第1項之藥學組成物,其為膠 ir.< —p. . m n> is, ^ 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4438861 | 1994-11-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW492876B true TW492876B (en) | 2002-07-01 |
Family
ID=6532126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW084108225A TW492876B (en) | 1994-11-03 | 1995-08-08 | New dosage forms of cyclosporine for oral application with single composition and high bioavailability and usual procedure of their manufacture |
Country Status (27)
Country | Link |
---|---|
US (1) | US6486124B2 (zh) |
EP (1) | EP0789580B1 (zh) |
JP (1) | JP3833248B2 (zh) |
KR (1) | KR970704464A (zh) |
CN (1) | CN1121238C (zh) |
AT (1) | ATE218359T1 (zh) |
AU (1) | AU715165B2 (zh) |
BG (1) | BG62955B1 (zh) |
BR (1) | BR9509550A (zh) |
CA (1) | CA2231404C (zh) |
CZ (1) | CZ287806B6 (zh) |
DE (2) | DE59510233D1 (zh) |
DK (1) | DK0789580T3 (zh) |
EE (1) | EE03425B1 (zh) |
ES (1) | ES2177652T3 (zh) |
FI (1) | FI118722B (zh) |
HU (1) | HUT77283A (zh) |
LT (1) | LT4306B (zh) |
LV (1) | LV11884B (zh) |
NO (1) | NO970741L (zh) |
PL (1) | PL183579B1 (zh) |
PT (1) | PT789580E (zh) |
RU (1) | RU2158601C2 (zh) |
SK (1) | SK164796A3 (zh) |
TR (1) | TR199501361A2 (zh) |
TW (1) | TW492876B (zh) |
WO (1) | WO1996014079A1 (zh) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2177652T3 (es) | 1994-11-03 | 2002-12-16 | Novartis Ag | Nuevas formas de preparacion de ciclosporina para la aplicacion oral con composicion simple y alta biodisponibilidad, y procedimiento para su obtencion. |
ATE263550T1 (de) * | 1995-08-25 | 2004-04-15 | Sangstat Medical Corp | Orale cyclosporinformulierungen |
US5834017A (en) * | 1995-08-25 | 1998-11-10 | Sangstat Medical Corporation | Oral cyclopsporin formulations |
US5766629A (en) * | 1995-08-25 | 1998-06-16 | Sangstat Medical Corporation | Oral cyclosporin formulations |
US5962019A (en) * | 1995-08-25 | 1999-10-05 | Sangstat Medical Corporation | Oral cyclosporin formulations |
DE19544507B4 (de) | 1995-11-29 | 2007-11-15 | Novartis Ag | Cyclosporin enthaltende Präparate |
AU762247B2 (en) * | 1997-01-30 | 2003-06-19 | Novartis Ag | Oil-free pharmaceutical compositions containing cyclosporin A |
RU2211047C2 (ru) | 1997-01-30 | 2003-08-27 | Новартис Аг | Желатиновые капсулы с твердым покрытием, включающие фармацевтические композиции, практически не содержащие масел |
DE19821951A1 (de) * | 1998-05-15 | 1999-11-18 | Basf Ag | Cyclosporin-Zubereitungen |
AUPP627498A0 (en) | 1998-10-02 | 1998-10-22 | University Of Queensland, The | Novel peptides - i |
US6656504B1 (en) | 1999-09-09 | 2003-12-02 | Elan Pharma International Ltd. | Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
US6506742B2 (en) | 1999-12-13 | 2003-01-14 | Ortho-Mcneil Pharmaceutical, Inc. | Soluble contraceptive liquid formulation |
EP1578787B1 (en) | 2002-12-02 | 2012-11-14 | Xenome Ltd | Novel chi-conotoxin peptides (-ii) |
JP4565087B2 (ja) | 2002-12-02 | 2010-10-20 | ゼノム リミティッド | 新規なχ−コノトキシン・ペプチド(−I) |
SE0301119D0 (sv) * | 2003-04-14 | 2003-04-14 | Astrazeneca Ab | New non-ionic surfactants for solubilizing poorly soluble molecules |
WO2005016312A1 (en) | 2003-08-13 | 2005-02-24 | Nobex Corporation | Micro-particle fatty acid salt solid dosage formulations for therapeutic agents |
US20050059583A1 (en) | 2003-09-15 | 2005-03-17 | Allergan, Inc. | Methods of providing therapeutic effects using cyclosporin components |
US7135455B2 (en) * | 2004-11-15 | 2006-11-14 | Allergan, Inc | Methods for the therapeutic use of cyclosporine components |
US7151085B2 (en) * | 2004-11-15 | 2006-12-19 | Allergan, Inc. | Therapeutic methods using cyclosporine components |
AU2006235478B2 (en) | 2005-04-12 | 2011-07-21 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising cyclosporine |
US7288520B2 (en) | 2005-07-13 | 2007-10-30 | Allergan, Inc. | Cyclosporin compositions |
US7297679B2 (en) * | 2005-07-13 | 2007-11-20 | Allergan, Inc. | Cyclosporin compositions |
US7202209B2 (en) * | 2005-07-13 | 2007-04-10 | Allergan, Inc. | Cyclosporin compositions |
US7276476B2 (en) * | 2005-07-13 | 2007-10-02 | Allergan, Inc. | Cyclosporin compositions |
US20070015691A1 (en) * | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Cyclosporin compositions |
US20070015693A1 (en) * | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Cyclosporin compositions |
US7501393B2 (en) | 2005-07-27 | 2009-03-10 | Allergan, Inc. | Pharmaceutical compositions comprising cyclosporins |
US7745400B2 (en) * | 2005-10-14 | 2010-06-29 | Gregg Feinerman | Prevention and treatment of ocular side effects with a cyclosporin |
US9839667B2 (en) | 2005-10-14 | 2017-12-12 | Allergan, Inc. | Prevention and treatment of ocular side effects with a cyclosporin |
DK2779994T3 (da) * | 2011-11-15 | 2020-05-18 | Allergan Inc | Suspensioner af cyclosporin a form 2 |
WO2013074608A1 (en) * | 2011-11-15 | 2013-05-23 | Allergan, Inc. | Cyclosporine a form 2 and method of making same |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1274354A (fr) | 1956-03-10 | 1961-10-27 | Agents tensio-actifs obtenus à partir de triglycérides et polyéthylène glycol | |
GB1171125A (en) | 1966-06-08 | 1969-11-19 | Glaxo Lab Ltd | Improvements in or relating to Injectable Preparations |
US3813345A (en) | 1971-08-05 | 1974-05-28 | Vanguard Chem Co Inc | Method of producing microcolloidal aqueous emulsions of unsaturated organic compounds |
US3954967A (en) | 1971-08-05 | 1976-05-04 | Vanguard Chemical Company, Inc. | Method of producing microcolloidal aqueous emulsions of unsaturated organic insecticidal compounds |
DE2455859C2 (de) | 1973-12-06 | 1983-12-15 | Sandoz-Patent-GmbH, 7850 Lörrach | Das Antibiotikum Cyclosporin A (S 7481/F-1), seine Herstellung und Verwendung |
US4073943A (en) | 1974-09-11 | 1978-02-14 | Apoteksvarucentralen Vitrum Ab | Method of enhancing the administration of pharmalogically active agents |
US4117118A (en) | 1976-04-09 | 1978-09-26 | Sandoz Ltd. | Organic compounds |
US4146499A (en) | 1976-09-18 | 1979-03-27 | Rosano Henri L | Method for preparing microemulsions |
JPS53107408A (en) | 1977-02-28 | 1978-09-19 | Yamanouchi Pharmaceut Co Ltd | Micellar preparation for rectal infusion |
FI65914C (fi) | 1978-03-07 | 1984-08-10 | Sandoz Ag | Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a |
CH636013A5 (en) | 1978-03-07 | 1983-05-13 | Sandoz Ag | More readily absorbable pharmaceutical composition |
CH641356A5 (en) | 1979-02-27 | 1984-02-29 | Sandoz Ag | Pharmaceutical compositions containing cyclosporin |
AU543727B2 (en) | 1980-06-02 | 1985-05-02 | Ayerst Mckenna & Harrison Inc. | Injectable composition of rapamycin |
FR2502951B1 (fr) | 1981-04-06 | 1985-12-06 | Sandoz Sa | Compositions pharmaceutiques topiques sous forme d'une micro-emulsion |
AU558155B2 (en) | 1982-02-01 | 1987-01-22 | Sandoz Ltd. | Treating multiple sclerosis with dihydro-cyclosporin d |
DE3225706C2 (de) | 1982-07-09 | 1984-04-26 | A. Nattermann & Cie GmbH, 5000 Köln | Flüssige Wirkstofformulierungen in Form von Konzentraten für Mikroemulsionen |
DE3235612A1 (de) | 1982-09-25 | 1984-03-29 | Bayer Ag, 5090 Leverkusen | Mikroemulsionen |
DE3237814A1 (de) | 1982-10-12 | 1984-04-12 | Warner-Lambert Co., 07950 Morris Plains, N.J. | Wasserfreie emulsionen und verwendung derselben |
DE3315805A1 (de) | 1983-04-30 | 1984-11-08 | Bayer Ag, 5090 Leverkusen | Wirkstoffzubereitungen |
JPS6061535A (ja) | 1983-08-24 | 1985-04-09 | エフ・ホフマン・ラ・ロシユ・ウント・コンパニ−・アクチエンゲゼルシヤフト | 製薬学的組成物 |
FR2553661B1 (fr) | 1983-10-19 | 1985-12-20 | Rhone Poulenc Sante | Nouvelles microemulsions pharmaceutiquement acceptables |
DE3406497A1 (de) | 1984-02-23 | 1985-09-05 | Mueller Bernhard Willi Werner | Hochdisperse pharmazeutische mehrkomponentensysteme und verfahren zu ihrer herstellung |
US4963367A (en) | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
US4794000A (en) | 1987-01-08 | 1988-12-27 | Synthetic Blood Corporation | Coacervate-based oral delivery system for medically useful compositions |
GB8903804D0 (en) | 1989-02-20 | 1989-04-05 | Sandoz Ltd | Improvements in or relating to organic compounds |
US5639724A (en) | 1984-07-24 | 1997-06-17 | Sandoz Ltd. | Cyclosporin galenic forms |
EP0365044A3 (en) | 1984-08-02 | 1990-08-22 | Sandoz Ag | Novel pharmaceutical use of (nva)2-cyclosporine |
CH662944A5 (it) | 1984-10-18 | 1987-11-13 | Pier Luigi Prof Dr Luisi | Procedimento per la preparazione di biocompatibili di micelle inverse di biocompatibili e loro utilizzazione. |
JPS61280435A (ja) | 1985-04-04 | 1986-12-11 | Kanji Takada | サイクロスポリン類のリンパ指向性製剤 |
JPS61249918A (ja) | 1985-04-26 | 1986-11-07 | Yutaka Mizushima | 点眼剤 |
IL78929A0 (en) | 1985-07-29 | 1986-09-30 | Abbott Lab | Microemulsion compositions for parenteral administration |
US5023271A (en) | 1985-08-13 | 1991-06-11 | California Biotechnology Inc. | Pharmaceutical microemulsions |
US4797272A (en) | 1985-11-15 | 1989-01-10 | Eli Lilly And Company | Water-in-oil microemulsions for cosmetic uses |
SE457693B (sv) | 1986-07-01 | 1989-01-23 | Drilletten Ab | Komposition med reglerad frigoering vari ett biologiskt material aer loest eller dispergerat i en l2-fas |
EP0256856A3 (en) | 1986-08-14 | 1989-01-11 | Synthetic Blood Corporation | A parenterally administrable composition |
DE3629386A1 (de) | 1986-08-29 | 1988-03-03 | Scherer Gmbh R P | Gelatinekapseln und verfahren zu ihrer herstellung |
DE3707711A1 (de) | 1987-03-11 | 1988-09-22 | Hoechst Ag | Oel-in-wasser-emulsionen, verfahren zu deren herstellung und deren verwendung |
CA1301642C (en) | 1987-03-30 | 1992-05-26 | Howard Bernard Dawson | Chemical formulations |
US4798823A (en) | 1987-06-03 | 1989-01-17 | Merck & Co., Inc. | New cyclosporin analogs with modified "C-9 amino acids" |
ATE95193T1 (de) | 1987-06-17 | 1993-10-15 | Sandoz Ag | Cyclosporine und deren benutzung als arzneimittel. |
GB2206119B (en) | 1987-06-22 | 1990-10-31 | Merck & Co Inc | A new cyclosporin derivative with modified "8-amino acid" |
US4835002A (en) | 1987-07-10 | 1989-05-30 | Wolf Peter A | Microemulsions of oil in water and alcohol |
HU205010B (en) | 1987-09-15 | 1992-03-30 | Sandoz Ag | Process for producing pharmaceutical compositions comprising compounds soluble up to 1 per cent and having medical activity |
US5756450A (en) | 1987-09-15 | 1998-05-26 | Novartis Corporation | Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms |
IL88076A (en) | 1987-10-28 | 1993-01-14 | Nippon Shinyaku Co Ltd | Fat emulsions as drug carriers |
US4914188A (en) | 1987-11-16 | 1990-04-03 | Merck & Co., Inc. | Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin |
HU203564B (en) | 1987-12-21 | 1991-08-28 | Sandoz Ag | Process for producing new orthorombos cyclosporin without solvatation |
EP0327280B1 (en) | 1988-01-29 | 1992-03-18 | Sankyo Company Limited | Cyclosporin compositions |
CH679119A5 (zh) | 1988-05-13 | 1991-12-31 | Sandoz Ag | |
HU201567B (en) * | 1988-07-21 | 1990-11-28 | Gyogyszerkutato Intezet | Process for production of intravenous medical compositions containing cyclosphorin |
GB2222770B (en) | 1988-09-16 | 1992-07-29 | Sandoz Ltd | Pharmaceutical compositions containing cyclosporins |
US5342625A (en) | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
EP0361928B1 (en) | 1988-09-29 | 1994-04-27 | Shiseido Company Limited | Emulsified composition |
CH679210A5 (zh) | 1988-10-26 | 1992-01-15 | Sandoz Ag | |
AU5157590A (en) | 1989-02-06 | 1990-08-24 | Abbott Laboratories | Pharmaceutical compositions for oral administration |
GB2230440B (en) | 1989-02-09 | 1993-05-19 | Sandoz Ltd | Novel cyclosporin galenic forms |
US4996193A (en) | 1989-03-03 | 1991-02-26 | The Regents Of The University Of California | Combined topical and systemic method of administration of cyclosporine |
US5177110A (en) | 1989-10-27 | 1993-01-05 | Ciba-Geigy Corporation | Injectable parasiticidal composition |
HU207222B (en) | 1990-02-15 | 1993-03-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing eyedrops containing primycin |
US5260301A (en) | 1990-03-01 | 1993-11-09 | Fujisawa Pharmaceutical Co., Ltd. | Pharmaceutical solution containing FK-506 |
HU208491B (en) | 1990-11-27 | 1993-11-29 | Gyogyszerkutato Intezet | Process for producing oral pharmaceutical composition containing cyclosporin |
GB9113872D0 (en) | 1991-06-27 | 1991-08-14 | Sandoz Ag | Improvements in or relating to organic compounds |
US5206219A (en) | 1991-11-25 | 1993-04-27 | Applied Analytical Industries, Inc. | Oral compositions of proteinaceous medicaments |
GB9208712D0 (en) | 1992-04-22 | 1992-06-10 | Sandoz Ltd | Pharmaceutical compositions containing cyclosporin derivates |
EP0589843B1 (en) | 1992-09-25 | 2001-11-28 | Novartis AG | Pharmaceutical compositions containing cyclosporins |
CH686761A5 (de) | 1993-05-27 | 1996-06-28 | Sandoz Ag | Galenische Formulierungen. |
IL111003A0 (en) | 1993-09-30 | 1994-11-28 | American Home Prod | Multi-component oral rapamycin formulation |
KR0146671B1 (ko) * | 1994-02-25 | 1998-08-17 | 김충환 | 사이클로스포린-함유 분말 조성물 |
DE59409088D1 (de) | 1994-10-04 | 2000-02-24 | Lohmann Rudolf Lomapharm | Lösungen von Anthrachinonen zur parenteralen Applikation |
ES2177652T3 (es) | 1994-11-03 | 2002-12-16 | Novartis Ag | Nuevas formas de preparacion de ciclosporina para la aplicacion oral con composicion simple y alta biodisponibilidad, y procedimiento para su obtencion. |
-
1995
- 1995-07-19 ES ES95925707T patent/ES2177652T3/es not_active Expired - Lifetime
- 1995-07-19 AU AU29751/95A patent/AU715165B2/en not_active Ceased
- 1995-07-19 SK SK1647-96A patent/SK164796A3/sk unknown
- 1995-07-19 BR BR9509550A patent/BR9509550A/pt not_active Application Discontinuation
- 1995-07-19 JP JP51493496A patent/JP3833248B2/ja not_active Expired - Fee Related
- 1995-07-19 CA CA002231404A patent/CA2231404C/en not_active Expired - Fee Related
- 1995-07-19 DK DK95925707T patent/DK0789580T3/da active
- 1995-07-19 HU HU9702144A patent/HUT77283A/hu unknown
- 1995-07-19 RU RU97108682/14A patent/RU2158601C2/ru active
- 1995-07-19 WO PCT/DE1995/000951 patent/WO1996014079A1/de not_active Application Discontinuation
- 1995-07-19 KR KR1019970700361A patent/KR970704464A/ko not_active Application Discontinuation
- 1995-07-19 CN CN95196010A patent/CN1121238C/zh not_active Expired - Fee Related
- 1995-07-19 DE DE59510233T patent/DE59510233D1/de not_active Expired - Fee Related
- 1995-07-19 EP EP95925707A patent/EP0789580B1/de not_active Expired - Lifetime
- 1995-07-19 AT AT95925707T patent/ATE218359T1/de not_active IP Right Cessation
- 1995-07-19 PT PT95925707T patent/PT789580E/pt unknown
- 1995-07-19 EE EE9700112A patent/EE03425B1/xx not_active IP Right Cessation
- 1995-07-19 CZ CZ19963616A patent/CZ287806B6/cs not_active IP Right Cessation
- 1995-08-08 TW TW084108225A patent/TW492876B/zh active
- 1995-10-26 DE DE19539860A patent/DE19539860A1/de not_active Withdrawn
- 1995-11-02 TR TR95/01361A patent/TR199501361A2/xx unknown
-
1997
- 1997-01-06 BG BG101117A patent/BG62955B1/bg unknown
- 1997-01-09 LT LT97-002A patent/LT4306B/lt not_active IP Right Cessation
- 1997-02-14 FI FI970634A patent/FI118722B/fi active IP Right Grant
- 1997-02-18 NO NO970741A patent/NO970741L/no not_active Application Discontinuation
- 1997-05-14 LV LVP-97-94A patent/LV11884B/lv unknown
-
1998
- 1998-03-09 PL PL95318560A patent/PL183579B1/pl unknown
-
2001
- 2001-10-17 US US09/981,929 patent/US6486124B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW492876B (en) | New dosage forms of cyclosporine for oral application with single composition and high bioavailability and usual procedure of their manufacture | |
TW205035B (zh) | ||
TW587936B (en) | Pharmaceutical composition containing proton pump inhibitors | |
JP4170386B2 (ja) | 疎水性薬剤の投与システム | |
ES2200048T3 (es) | Composicion farmaceutica que contiene fenofibrato y gliceridos poliglicolizados. | |
TWI243060B (en) | Dispersion formulations containing lipase inhibitors | |
ES2226976T3 (es) | Formulaciones galenicas de fenofibrato y su procedimiento de obtencion. | |
TW201114766A (en) | Pharmaceutical composition for a hepatitis C viral protease inhibitor | |
MX2010013203A (es) | Forma de dosificacion farmaceutica en capsula que comprende una formulacion en suspension de un derivado de indolinona. | |
JPH03200728A (ja) | 医薬組成物 | |
CN106999558A (zh) | (17‑β)‑3‑氧雄甾‑4‑烯‑17‑基十一酸酯组合物及其制备方法和用途 | |
US4397835A (en) | Enterosoluble hard-capsulated medicaments | |
TW455491B (en) | Pharmaceutical composition for oral administration | |
Sarojini et al. | Oral medicated jellies–a review | |
WO2003101378A2 (en) | Pharmaceutical formulation in a drug delivery system and process for preparing the same | |
EP2036575B1 (en) | Pharmaceutical compositions for oral use for treating patients affected by obesity | |
WO2005007070A2 (en) | Stable pharmaceutical composition | |
JP7335256B2 (ja) | シメチコン及びロペラミドのエマルションの医薬製剤 | |
JP3277735B2 (ja) | ナフトエ酸誘導体の吸収促進組成物 | |
US7632853B2 (en) | Soluble, stable and concentrated pharmaceutical composition compromising ritonavir and process for preparing thereof | |
US20050175686A1 (en) | Drug delivery system using a solubilized gelatin shell composition and unit dose drug delivery using a special shape soft gelatin capsule | |
KR102770132B1 (ko) | 시메티콘 및 로페라미드의 에멀션을 위한 약제학적 제형 | |
TW528596B (en) | Oral liquid formulations of benzoxazinones HIV reverse transcriptase inhibitors | |
WO2014135965A1 (en) | Bismuth liquid filled hard capsules | |
KR20240057565A (ko) | 무메프랄을 함유하는 장내 유산균 증식 및 우울증 예방 또는 치료용 조성물 |